Clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. Clopidogrel also inhibits platelet aggregation induced by agonists other than ADP. Aspirin inhibits platelet aggregation by irreversible inhibition of platelet cyclooxygenase and thus inhibiting the generation of thromboxane A2 a powerful inducer of platelet aggregation and vasoconstriction.



    Aspin-Plus Tablet: Each film coated tablet contains Clopidogrel (as bisulphate) USP 75 mg plus Aspirin BP 75 mg.


    Aspin-Plus is indicated for the reduction of thrombotic events as follows:
    Recent MI, recent stroke or established peripheral arterial disease: For patients with a history of recent myocardial infarction (MI), recent stroke or established peripheral arterial disease, Aspin-Plus has been shown to reduce the rate of a combined endpoint of new ischemic stroke, new MI (fatal or not) and other vascular death.
    Acute coronary syndrome: For patients with acute coronary syndrome including patients who are to be managed with medically and those who are to be managed with percutaneous coronary intervention, Aspin-Plus has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, stroke or refractory ischemia.

Dosage & Administration

    The recommended daily dose is one tablet.
    Aspin-Plus can be administered with or without food.


    The use of Aspin-Plus is contraindicated in the following conditions:
    Hypersensitivity to the drug substance or any component of the product.
    Active pathological bleeding such as peptic ulcer or intracranial ulcer.

Warning & Precautions

    Use with caution in patients at increased risk of bleeding from trauma, surgery or other pathological conditions.
    Severe hepatic impairment: Use with caution in patients with severe hepatic disease.

Side effects

    This drug is generally well tolerated. Side effects that have been reported include chest pain, fatigue, edema, headache, dizziness, abdominal pain, dyspepsia, diarrhea, nausea, and depression.

Drug interaction

    Use caution with phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and non-steroidal anti-inflammatory agents.

Use in special groups

    Pregnancy: Aspin-Plus should be used during pregnancy only if clearly needed.
    Lactation: It is not known whether this drug is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the nursing woman.


    Aspin-Plus Tablet: Each box contains 30's tablets in alu-alu blister pack.